270 related articles for article (PubMed ID: 12719580)
41. N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.
Pancera M; Yang Y; Louder MK; Gorman J; Lu G; McLellan JS; Stuckey J; Zhu J; Burton DR; Koff WC; Mascola JR; Kwong PD
PLoS One; 2013; 8(2):e55701. PubMed ID: 23431362
[TBL] [Abstract][Full Text] [Related]
42. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
Pantophlet R; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
[TBL] [Abstract][Full Text] [Related]
43. Effects of a remote mutation from the contact paratope on the structure of CDR-H3 in the anti-HIV neutralizing antibody PG16.
Kondo HX; Kiribayashi R; Kuroda D; Kohda J; Kugimiya A; Nakano Y; Tsumoto K; Takano Y
Sci Rep; 2019 Dec; 9(1):19840. PubMed ID: 31882602
[TBL] [Abstract][Full Text] [Related]
44. Peptide Paratope Mimics of the Broadly Neutralizing HIV-1 Antibody b12.
Haußner C; Damm D; Nirschl S; Rohrhofer A; Schmidt B; Eichler J
Chembiochem; 2017 Apr; 18(7):647-653. PubMed ID: 28125767
[TBL] [Abstract][Full Text] [Related]
45. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
46. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
Bagley J; Dillon PJ; Rosen C; Robinson J; Sodroski J; Marasco WA
Mol Immunol; 1994 Oct; 31(15):1149-60. PubMed ID: 7935503
[TBL] [Abstract][Full Text] [Related]
47. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
48. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.
Parren PW; Ditzel HJ; Gulizia RJ; Binley JM; Barbas CF; Burton DR; Mosier DE
AIDS; 1995 Jun; 9(6):F1-6. PubMed ID: 7662189
[TBL] [Abstract][Full Text] [Related]
49. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Zhou T; Georgiev I; Wu X; Yang ZY; Dai K; Finzi A; Kwon YD; Scheid JF; Shi W; Xu L; Yang Y; Zhu J; Nussenzweig MC; Sodroski J; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
Science; 2010 Aug; 329(5993):811-7. PubMed ID: 20616231
[TBL] [Abstract][Full Text] [Related]
50. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A; Honnen WJ; Racho ME; Tilley SA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
[TBL] [Abstract][Full Text] [Related]
51. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.
Persson H; Ye W; Wernimont A; Adams JJ; Koide A; Koide S; Lam R; Sidhu SS
J Mol Biol; 2013 Feb; 425(4):803-11. PubMed ID: 23219464
[TBL] [Abstract][Full Text] [Related]
52. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
[TBL] [Abstract][Full Text] [Related]
53. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
[TBL] [Abstract][Full Text] [Related]
54. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.
Cale EM; Gorman J; Radakovich NA; Crooks ET; Osawa K; Tong T; Li J; Nagarajan R; Ozorowski G; Ambrozak DR; Asokan M; Bailer RT; Bennici AK; Chen X; Doria-Rose NA; Druz A; Feng Y; Joyce MG; Louder MK; O'Dell S; Oliver C; Pancera M; Connors M; Hope TJ; Kepler TB; Wyatt RT; Ward AB; Georgiev IS; Kwong PD; Mascola JR; Binley JM
Immunity; 2017 May; 46(5):777-791.e10. PubMed ID: 28514685
[TBL] [Abstract][Full Text] [Related]
55. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X
Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016
[TBL] [Abstract][Full Text] [Related]
56. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.
Parren PW; Mondor I; Naniche D; Ditzel HJ; Klasse PJ; Burton DR; Sattentau QJ
J Virol; 1998 May; 72(5):3512-9. PubMed ID: 9557629
[TBL] [Abstract][Full Text] [Related]
57. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
[TBL] [Abstract][Full Text] [Related]
58. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes.
Llorente M; Sánchez-Palomino S; Mañes S; Lucas P; Kremer L; De Alborán IM; Torán JL; Alcamí J; Del Real G; Martínez-A C
Scand J Immunol; 1999 Sep; 50(3):270-9. PubMed ID: 10447936
[TBL] [Abstract][Full Text] [Related]
59. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
[TBL] [Abstract][Full Text] [Related]
60. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.
Barbas CF; Björling E; Chiodi F; Dunlop N; Cababa D; Jones TM; Zebedee SL; Persson MA; Nara PL; Norrby E
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9339-43. PubMed ID: 1384050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
